Detalhe da pesquisa
1.
Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells.
Cancer Immunol Immunother
; 73(3): 60, 2024 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38400933
2.
The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.
J Transl Med
; 20(1): 179, 2022 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35449104
3.
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
Lancet Oncol
; 22(1): 118-131, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33387490
4.
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity.
Cancer Discov
; : OF1-OF15, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38588588
5.
Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development.
J Immunother Cancer
; 11(7)2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37487665
6.
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors.
J Immunother Cancer
; 11(3)2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36918224
7.
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.
Cancer Cell
; 3(4): 363-75, 2003 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-12726862
8.
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.
J Immunother Cancer
; 10(1)2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35074903
9.
Hallmarks of Resistance to Immune-Checkpoint Inhibitors.
Cancer Immunol Res
; 10(4): 372-383, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35362046
10.
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
Nat Med
; 28(6): 1167-1177, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35662283
11.
CD22 as a target for cancer therapy.
J Exp Ther Oncol
; 9(3): 241-8, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-22070056
12.
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.
J Immunother Cancer
; 8(1)2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32238470
13.
Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia.
Circ Res
; 101(12): 1310-8, 2007 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-17932327
14.
Synthesis, antiproliferative, and pharmacokinetic properties of 3- and 17-double-modified analogs of 2-methoxyestradiol.
Bioorg Med Chem Lett
; 19(21): 6241-4, 2009 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19782564
15.
Synthesis and antitumor activities of 3-modified 2-methoxyestradiol analogs.
Bioorg Med Chem Lett
; 19(22): 6459-62, 2009 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19782568
16.
Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure-activity relationships compared to 2-methoxyestradiol.
Bioorg Med Chem
; 17(20): 7344-52, 2009 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19762246
17.
Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198.
Mol Cancer Ther
; 7(6): 1472-82, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18566218
18.
It Is a Capital Mistake to Theorize Who to Treat with Checkpoint Inhibitors before One Has Data.
Trends Cancer
; 5(2): 79-82, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30755306
19.
Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.
Clin Cancer Res
; 25(19): 5752-5758, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31308059
20.
HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.
Sci Rep
; 9(1): 9130, 2019 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31235758